For long-term investors looking to ride the wave of AI-powered productivity, UiPath might just be one of the more underappreciated names worth watching closely.

Learn the art of writing clear, structured prompts for AI tools like ChatGPT. Save time, reduce frustration, and easily get ...

The standing of UiPath among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ...

If you're looking for companies quietly shaping the next wave of AI-driven productivity, UiPath deserves a closer look.

The combination measles, mumps and rubella vaccine — better known as the MMR shot —should be split into three separate vaccines, US Centers for Disease Control and Prevention Acting Director Jim ...

Click to share on Facebook (Opens in new window) Facebook Click to share on X (Opens in new window) X Kidman, 58, opened up about how she views her sartorial choices while chatting with Vogue for the ...

In the current session, the stock is trading at $14.79, after a 1.86% increase. Over the past month, UiPath Inc. (NYSE:PATH) stock increased by 24.54%, and in the past year, by 19.13%. With ...

Bears second-year tackle Theo Benedet always has a tough assignment, not as dificult as last week but a challenge nonetheless. Bears coach Ben Johnson hasn't said Benedet is a starter or backup, or at ...

INDIANAPOLIS — Global agriculture technology company Corteva announced Tuesday it will separate into two independent, publicly traded companies. Company leaders say the move will sharpen focus and ...

The latest trends and issues around the use of open source software in the enterprise. UiPath used its annual user/practitioner and partner/customer symposium this month to detail a new union with ...

NEW YORK--(BUSINESS WIRE)-- UiPath (PATH), a global leader in agentic automation, today announced a collaboration with OpenAI to build a ChatGPT connector integrating OpenAI frontier models with ...

AnaptysBio plans to split into two publicly traded companies, with one entity taking forward the biopharma’s clinical-stage pipeline and the other overseeing its royalty-based agreements. The crown ...